A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Diego Cadavid, MD
Verge Genomics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uz Leuven
Leuven, Flemish Brabant, Belgium
- Stan Cassidy Centre for Rehabilitation (horizon Nb)
Montreal, Quebec, Canada
- the Neuro - Montréal Neurological Institute-Hospital
Montreal, Quebec, Canada
- University of Eastern Finland, Brain Research Unit
Kuopio, Eastern Finland, Finland
- Helsinki University Hospital
Helsinki, Uusimaa, Finland
- Turku University Hospital
Turku, Western Finland, Finland
- University Medical Center Utrecht
Utrecht, Netherlands
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Jan 2024
- Primary completion
- 7 Jul 2025
- Completion
- 7 Jul 2025
- Last update posted
- 15 Dec 2025
- Registered enrollment
- 54
- Registry id
- NCT06215755
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.